Indegene Limited announced its FY 2024-25 annual report and the convening of its Annual General Meeting (AGM). The 27th AGM will be held on Thursday, June 26, 2025, at 4:30 p.m. IST via video conferencing. The annual report includes key details on Indegene’s financial performance, strategic initiatives, and commitment to sustainability and community engagement. Shareholders are invited to participate in the AGM to discuss the company’s performance and future direction.
Financial Performance
In FY 2024-25, Indegene Limited reported a revenue of ₹28,393 million (US$ 335.7 million), a 9.6% year-over-year increase. The company’s EBITDA reached ₹5,622 million, and profit after tax (PAT) grew by 20.8% to ₹4,067 million. The Board has recommended a final dividend, while continuing focus on value-accretive acquisitions.
The company achieved growth across business segments, with Enterprise Commercial Solutions and Enterprise Medical Solutions growing by 12.2% (₹23,896 million), representing 84.2% of revenues. Omnichannel Activation Solutions grew by 9.0% to ₹3,477 million.
Strategic Initiatives
Indegene has strengthened its capabilities in Al, integrating it into existing services and launching Cortex, its GenAl platform. Investments in GenAl are ongoing, with talent training via the ‘GenAl @ Work’ initiative. The company also focuses on delivering practical Al solutions rooted in real-world experience.
Sustainability and Community
Indegene achieved a Silver rating from EcoVadis, placing it among the top 15% of companies for sustainability. Partnerships with organizations like C-CAMP, IISc, and Plaksha University reflect a commitment to community and strengthening India’s healthcare ecosystem.
Board Meeting Outcomes
The Board of Directors has recommended a final dividend of ₹2 per equity share, subject to shareholder approval at the AGM. The 27th Annual General Meeting of the Company is scheduled on Thursday, June 26, 2025 at 4:30 p.m. IST through video conferencing.
Source: BSE
